<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39421748</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Exploring pathogen population density as a metric for understanding post-COVID infectious disease surges.</ArticleTitle><Pagination><StartPage>1459628</StartPage><MedlinePgn>1459628</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1459628</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1459628</ELocationID><Abstract><AbstractText>After the easing of COVID-19 restrictions, peaks of common infectious diseases surpassed pre-pandemic levels, raising questions about causes and ways to monitor these changes. A proposed measure, the Pathogen Population Density (PPD) score, could help track these shifts. PPD refers to the concentration of infectious agents within a population at a given time and location, serving as a potential indicator of infection levels in susceptible individuals at the population level. It is likely that PPD remains relatively stable within a specific community, as an equilibrium forms between infections and susceptibility. During the pandemic, nonpharmaceutical interventions (NPIs) led to a reduction in infectious diseases, possibly lowering population immunity and decreasing the PPD score. Once NPIs were lifted, the PPD score likely increased sharply due to a larger pool of susceptible individuals, causing more primary infections and stronger recurrent infections, faster transmission, and more severe pathogenic outcomes at the individual level. Monitoring the PPD score over time could help predict when infection peaks will occur. PPD is influenced by factors such as public health strategies, vaccination programs, and the behavior of high-risk individuals. As a quantitative measure, PPD has the potential to serve as a valuable predictive and monitoring tool, helping public health officials anticipate and track changes in infectious disease dynamics. It could be an effective tool for managing future outbreaks or pandemics and serve as a communication tool between scientists and the public to understand the emergence of new disease peaks.</AbstractText><CopyrightInformation>Copyright © 2024 Zhang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Luwen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, Nebraska Center for Virology, University of Nebraska, Lincoln, NE, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011156" MajorTopicYN="N">Population Density</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">herd immunity</Keyword><Keyword MajorTopicYN="N">host resistance</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">population</Keyword><Keyword MajorTopicYN="N">post-COVID surge</Keyword></KeywordList><CoiStatement>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>4</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39421748</ArticleId><ArticleId IdType="pmc">PMC11484442</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1459628</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. (2020) 56:106054. doi: 10.1016/j.ijantimicag.2020.106054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106054</ArticleId><ArticleId IdType="pmc">PMC7286265</ArticleId><ArticleId IdType="pubmed">32534188</ArticleId></ArticleIdList></Reference><Reference><Citation>del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. (2020) 324:1723–4. doi: 10.1001/jama.2020.19719</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen HM, et al. . An evidence review of face masks against COVID-19. Proc Natl Acad Sci United States America. (2021) 118. doi: 10.1073/pnas.2014564118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2014564118</ArticleId><ArticleId IdType="pmc">PMC7848583</ArticleId><ArticleId IdType="pubmed">33431650</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters JA, Farhadloo M. The effects of non-pharmaceutical interventions on COVID-19 cases, hospitalizations, and mortality: A systematic literature review and meta-analysis. AJPM Focus. (2023) 2:100125. doi: 10.1016/j.focus.2023.100125</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.focus.2023.100125</ArticleId><ArticleId IdType="pmc">PMC10265928</ArticleId><ArticleId IdType="pubmed">37362389</ArticleId></ArticleIdList></Reference><Reference><Citation>Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. . Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. Bmj. (2021) 375:e068302. doi: 10.1136/bmj-2021-068302</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068302</ArticleId><ArticleId IdType="pmc">PMC9423125</ArticleId><ArticleId IdType="pubmed">34789505</ArticleId></ArticleIdList></Reference><Reference><Citation>Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics. (2021) 148. doi: 10.1542/peds.2021-052089</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-052089</ArticleId><ArticleId IdType="pubmed">34108234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, et al. . Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. (2021) 51:418–23. doi: 10.1016/j.idnow.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8114587</ArticleId><ArticleId IdType="pubmed">33991720</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Centre for Disease, P., &amp; Control . Increase in pertussis cases in EU/EEA: infants under six months of age at the highest risk (2024). Available online at: https://www.ecdc.europa.eu/en/news-events/increase-pertussis-cases-eueea-infants-under-six-months-age-highest-risk (Accessed July 01, 2024).</Citation></Reference><Reference><Citation>Foley DA, Yeoh DK, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, et al. . The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis. (2021) 73:e2829–30. doi: 10.1093/cid/ciaa1906</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1906</ArticleId><ArticleId IdType="pmc">PMC7929151</ArticleId><ArticleId IdType="pubmed">33594407</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg-Bockhorn E, Hurzlmeier C, Vahl JM, Stupp F, Janda A, von Baum H, et al. . Increase in acute mastoiditis at the end of the COVID-19 pandemic. Eur Arch Oto-Rhino-Laryngology. (2024) 281(9):4747–56. doi: 10.1007/s00405-024-08704-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-024-08704-y</ArticleId><ArticleId IdType="pmc">PMC11393142</ArticleId><ArticleId IdType="pubmed">38740579</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, et al. . Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States 2020-2021. MMWR Morb Mortal Wkly Rep. (2021) 70:1013–9. doi: 10.15585/mmwr.mm7029a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7029a1</ArticleId><ArticleId IdType="pmc">PMC8297694</ArticleId><ArticleId IdType="pubmed">34292924</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. A review of the resurgence of measles, a vaccine-preventable disease, as current concerns contrast with past hopes for measles elimination. Med Sci Monit. (2024) 30:e944436. doi: 10.12659/msm.944436</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/msm.944436</ArticleId><ArticleId IdType="pmc">PMC10946219</ArticleId><ArticleId IdType="pubmed">38525549</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira A, Wan Y, Ryan Y, Li HK, Guy RL, Papangeli M, et al. . Rapid expansion and international spread of M1UK in the post-pandemic UK upsurge of Streptococcus pyogenes. Nat Commun. (2024) 15:3916. doi: 10.1038/s41467-024-47929-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-47929-7</ArticleId><ArticleId IdType="pmc">PMC11087535</ArticleId><ArticleId IdType="pubmed">38729927</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L. From imprecise “immune debt” to nuanced “immune shortage”? Infect Dis Now. (2024) 54:104894. doi: 10.1016/j.idnow.2024.104894</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2024.104894</ArticleId><ArticleId IdType="pubmed">38548017</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova JL, Abel L. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell. (2022) 185:3086–103. doi: 10.1016/j.cell.2022.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.07.004</ArticleId><ArticleId IdType="pmc">PMC9386946</ArticleId><ArticleId IdType="pubmed">35985287</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunmire SK, Verghese PS, Balfour HH. Primary Epstein-Barr virus infection. J Clin Virol. (2018) 102:84–92. doi: 10.1016/j.jcv.2018.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2018.03.001</ArticleId><ArticleId IdType="pubmed">29525635</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. (2021) 21:456. doi: 10.1186/s12879-021-06147-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06147-y</ArticleId><ArticleId IdType="pmc">PMC8135979</ArticleId><ArticleId IdType="pubmed">34016040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullen M, Heriot GS, Jamrozik E. Herd immunity, vaccination and moral obligation. J Med Ethics. (2023) 49:636–41. doi: 10.1136/jme-2022-108485</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jme-2022-108485</ArticleId><ArticleId IdType="pmc">PMC10511978</ArticleId><ArticleId IdType="pubmed">37277175</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai AN, Majumder MS. What is herd immunity? JAMA. (2020) 324:2113–3. doi: 10.1001/jama.2020.20895</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.20895</ArticleId><ArticleId IdType="pubmed">33074287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok KO, Lai F, Wei WI, Wong SYS, Tang JWT. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. (2020) 80:e32–3. doi: 10.1016/j.jinf.2020.03.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.027</ArticleId><ArticleId IdType="pmc">PMC7151357</ArticleId><ArticleId IdType="pubmed">32209383</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol. (2008) 82:2040–55. doi: 10.1128/jvi.01625-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01625-07</ArticleId><ArticleId IdType="pmc">PMC2258918</ArticleId><ArticleId IdType="pubmed">17928346</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton A, Lello J, Bonsall MB. Pathogen responses to host immunity: the impact of time delays and memory on the evolution of virulence. Proc Biol Sci. (2006) 273:2083–90. doi: 10.1098/rspb.2006.3552</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rspb.2006.3552</ArticleId><ArticleId IdType="pmc">PMC1635473</ArticleId><ArticleId IdType="pubmed">16846917</ArticleId></ArticleIdList></Reference><Reference><Citation>Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. (1986) 140:543–6. doi: 10.1001/archpedi.1986.02140200053026</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpedi.1986.02140200053026</ArticleId><ArticleId IdType="pubmed">3706232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton BE, Martin JA, Osterman MJK. Births: provisional data for 2023. Natl Center Health Stat. (2024) 35. doi: 10.15620/cdc/151797</Citation><ArticleIdList><ArticleId IdType="doi">10.15620/cdc/151797</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci United States America. (2004) 101:6146–51. doi: 10.1073/pnas.0307506101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0307506101</ArticleId><ArticleId IdType="pmc">PMC395937</ArticleId><ArticleId IdType="pubmed">15071187</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartfield M, Alizon S. Introducing the outbreak threshold in epidemiology. PloS Pathog. (2013) 9:e1003277. doi: 10.1371/journal.ppat.1003277</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003277</ArticleId><ArticleId IdType="pmc">PMC3680036</ArticleId><ArticleId IdType="pubmed">23785276</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson HJ, Gakidou E, Murray CJL. The vaccine-hesitant moment. N Engl J Med. (2022) 387:58–65. doi: 10.1056/NEJMra2106441</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2106441</ArticleId><ArticleId IdType="pmc">PMC9258752</ArticleId><ArticleId IdType="pubmed">35767527</ArticleId></ArticleIdList></Reference><Reference><Citation>Packham A, Taylor AE, Karangwa MP, Sherry E, Muvunyi C, Green CA. Measles vaccine coverage and disease outbreaks: A systematic review of the early impact of COVID-19 in low and lower-middle income countries. Int J Public Health. (2024) 69:1606997. doi: 10.3389/ijph.2024.1606997</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/ijph.2024.1606997</ArticleId><ArticleId IdType="pmc">PMC11079172</ArticleId><ArticleId IdType="pubmed">38725903</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. (2022) 23:210–6. doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruf W. Immune damage in long covid. Science. (2024) 383:262–3. doi: 10.1126/science.adn1077</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adn1077</ArticleId><ArticleId IdType="pubmed">38236985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, et al. . Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. (2022) 20:26. doi: 10.1186/s12916-021-02228-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MR. Epstein-barr virus, the immune system, and associated diseases. Front Microbiol. (2011) 2:5. doi: 10.3389/fmicb.2011.00005</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2011.00005</ArticleId><ArticleId IdType="pmc">PMC3109484</ArticleId><ArticleId IdType="pubmed">21687403</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates BM, Staricha KL, Wiese KM, Ridge KM. Influenza A virus infection, innate immunity, and childhood. JAMA Pediatr. (2015) 169:956–63. doi: 10.1001/jamapediatrics.2015.1387</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2015.1387</ArticleId><ArticleId IdType="pmc">PMC4765914</ArticleId><ArticleId IdType="pubmed">26237589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. . Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. (2019) 366:599–606. doi: 10.1126/science.aay6485</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay6485</ArticleId><ArticleId IdType="pmc">PMC8590458</ArticleId><ArticleId IdType="pubmed">31672891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauce D, Larsen M, Fastenackels S, Duperrier A, Keller M, Grubeck-Loebenstein B, et al. . Evidence of premature immune aging in patients thymectomized during early childhood. J Clin Invest. (2009) 119:3070–8. doi: 10.1172/jci39269</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci39269</ArticleId><ArticleId IdType="pmc">PMC2752077</ArticleId><ArticleId IdType="pubmed">19770514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM. HIV as a cause of immune activation and immunosenescence. Mediators Inflammation. (2017) 2017:6825493. doi: 10.1155/2017/6825493</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/6825493</ArticleId><ArticleId IdType="pmc">PMC5676471</ArticleId><ArticleId IdType="pubmed">29209103</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>